SimulScreen™ Blocking Assay - SARS-CoV-2 Case Study
In this poster presentation, SCT's COO Allison Schulkins presents SCT's work on a novel blocking assay as part of SimulScreen™ assays. This case study on SARS-CoV-2 grouped results into non-blocking and blocking antibodies in the primary screen by using a recombinant ACE2 screen to distinguish antibodies with overlapping epitopes with the Spike protein receptor.
Over 1500 RBD-specific antibody sequences were recovered. Of those antigen-binding antibodies, 435 were identified as potential blockers. 17 antibodies were reconstructed to validate the assay using a pseudovirus assay. The pseudovirus assay showed 86% of blocking antibodies had neutralization activity. Two non-blocking assays were also reconstructed and showed low or no neutralization activity in the pseudovirus assay.
Our novel blocking assay showed a high correlation with blocking activity from SCT's novel blocking assay and neutralization of the virus using the pseudovirus.
View the presentation here:
SARS-CoV-2 Neutralizing Antibodies Discovered Fast: A Novel Upfront Blocking Assay to Speed to the Finish from Allison Schulkins on Vimeo.
Download the Poster